Combination treatment for esophageal cancer after immunotherapy
Part of Cancer, Digestive system clinical trials.
This study tests a new combination of two drugs (SHR-1701 and irinotecan liposome) for people with esophageal squamous cell carcinoma whose cancer has returned or spread after prior immunotherapy. The goal is to see if this combination can help shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with esophageal squamous cell carcinoma (a type of esophageal cancer) that is confirmed by biopsy or other lab tests.
- You have already been treated with immunotherapy, and this trial is for a second line of treatment (for when the first line stops working).
- You are 18 years or older and your general health is good enough that you are able to care for yourself and are not bedridden (ECOG 0 or 1).
- You have at least one measurable tumor on a scan (such as CT or MRI) that can be tracked during the study.
- Your organ function (liver, kidney, blood counts) is within acceptable limits as determined by blood tests.
- If you are female of childbearing potential, you must have a negative pregnancy test, agree to use effective birth control for 6 months after the last dose, and not breastfeed. If you are male with a partner of childbearing potential, you must use effective birth control for 3 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs for people with esophageal squamous cell carcinoma that is advanced or has spread. The goal is to see if the combination can help shrink tumors or slow the disease.
This trial tests whether combining two immunotherapy drugs (which boost your immune system to fight cancer) with a standard chemotherapy drug before surgery can improve outcomes for people with esophageal cancer that can be removed. The goal is to see if this approach shrinks the tumor and helps you live longer.
This trial tests a new combination of drugs (QL1706, nab-paclitaxel, and cisplatin) as a first treatment for advanced or metastatic esophageal squamous cell carcinoma. The goal is to see if this combination is safe and effective in shrinking tumors and helping patients live longer.
This trial tests a combination of two drugs for advanced esophageal cancer that has grown despite earlier treatment. The goal is to see if this combination can help shrink tumors and slow the disease.
This trial tests a combination of two chemotherapy drugs (liposomal irinotecan and 5-FU) for people with advanced esophageal cancer that didn't improve after first-line treatment. The goal is to see if this new combination can help shrink tumors or slow their growth.
This study tests a new treatment for people with locally advanced esophageal cancer that did not respond to initial chemotherapy and immunotherapy. The goal is to see if the study drug can shrink or control the cancer when surgery is not an option.
Hear when a new ESCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.